A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment

NCT ID: NCT00004581

Last Updated: 2009-02-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the safety and effectiveness of 2 anti-HIV drug combinations in HIV-infected patients. Both combinations will include nevirapine (NVP), 2 nucleoside reverse transcriptase inhibitors (NRTIs), and at least 1 protease inhibitor (PI). One combination will include a new protease inhibitor, ABT-378, combined in a capsule with ritonavir (RTV).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients receive 1 of the following:

1. ABT-378/RTV plus NVP plus 2 NRTIs; or
2. Investigator-selected PI(s) plus NVP plus 2 NRTIs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lopinavir/Ritonavir

Intervention Type DRUG

Nevirapine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients may be eligible for this study if they:

* Are at least 12 years old.
* Are HIV-positive and have a viral load (level of HIV in the blood) of 1,000 - 100,000 copies/ml.
* Are currently taking an anti-HIV drug combination that includes 1 PI and 2 NRTIs, and that has not been changed in at least 12 weeks.
* Are naive to (have never taken) at least 1 NRTI, other than zalcitabine or abacavir.
* Agree to abstinence or use of an effective barrier method (e.g., condom) of birth control.

Exclusion Criteria

Patients will not be eligible for this study if they:

* Have an active illness.
* Have received treatment for any active opportunistic (AIDS-related) infection within 30 days of study entry.
* Have ever received a nonnucleoside reverse transcriptase inhibitor (NNRTI).
* Have received investigational (not yet approved by the FDA) drugs within 30 days of study entry.
* Have received treatment with a PI other than their current PI.
* Are receiving chemotherapy for cancer.
* Are pregnant or breast-feeding.
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott

INDUSTRY

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Univ of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Phoenix Body Positive

Phoenix, Arizona, United States

Site Status

Pacific Oaks Med Group

Beverly Hills, California, United States

Site Status

Orange County Ctr for Special Immunology

Fountain Valley, California, United States

Site Status

AIDS Healthcare Foundation

Los Angeles, California, United States

Site Status

Tower ID Med Associates

Los Angeles, California, United States

Site Status

UCLA CARE Ctr

Los Angeles, California, United States

Site Status

San Francisco Veterans Administration Med Ctr

San Francisco, California, United States

Site Status

Harbor - UCLA Med Ctr

Torrance, California, United States

Site Status

Yale Univ / AIDS Clinical Trials Unit

New Haven, Connecticut, United States

Site Status

Univ of Miami School of Medicine

Miami, Florida, United States

Site Status

Infectious Disease Research Institute

Tampa, Florida, United States

Site Status

AIDS Research Consortium of Atlanta

Atlanta, Georgia, United States

Site Status

Emory Univ

Atlanta, Georgia, United States

Site Status

Cook County Hosp

Chicago, Illinois, United States

Site Status

AIDS Research Alliance - Chicago

Chicago, Illinois, United States

Site Status

Division of Inf Diseases/ Indiana Univ Hosp

Indianapolis, Indiana, United States

Site Status

Univ of Kansas School of Medicine

Wichita, Kansas, United States

Site Status

Tulane Univ Med School

New Orleans, Louisiana, United States

Site Status

Johns Hopkins Hosp

Baltimore, Maryland, United States

Site Status

Boston Med Ctr

Boston, Massachusetts, United States

Site Status

Community Research Initiative of New England

Brookline, Massachusetts, United States

Site Status

Univ of Michigan Hospitals and Health Ctrs

Ann Arbor, Michigan, United States

Site Status

Abbott Northwestern Hosp

Minneapolis, Minnesota, United States

Site Status

Saint Michael's Med Ctr / Dept of Infectious Diseases

Newark, New Jersey, United States

Site Status

St Michaels Med Ctr

Newark, New Jersey, United States

Site Status

Beth Israel Med Ctr

New York, New York, United States

Site Status

Cornell Clinical Trials Unit - Chelsea Clinic

New York, New York, United States

Site Status

Howard Grossman

New York, New York, United States

Site Status

SUNY / Health Sciences Ctr at Stony Brook

Stony Brook, New York, United States

Site Status

SUNY at Stony Brook / Div of Infectious Disease

Stony Brook, New York, United States

Site Status

Duke Univ Med Ctr / Infectious Disease Clinic

Durham, North Carolina, United States

Site Status

Holmes Hosp / Univ of Cincinnati Med Ctr

Cincinnati, Ohio, United States

Site Status

Associates in Med and Mental Health

Tulsa, Oklahoma, United States

Site Status

Oregon Health Sciences Univ

Portland, Oregon, United States

Site Status

Philadelphia FIGHT

Philadelphia, Pennsylvania, United States

Site Status

Stephen Hauptman

Philadelphia, Pennsylvania, United States

Site Status

The Miriam Hosp

Providence, Rhode Island, United States

Site Status

Oaklawn Physicians Group

Dallas, Texas, United States

Site Status

Univ of Texas Southwestern Med Ctr

Dallas, Texas, United States

Site Status

Univ of Texas / Med Branch at Galveston

Galveston, Texas, United States

Site Status

Joseph C Gathe

Houston, Texas, United States

Site Status

Univ of Utah Med School / Clinical Trials Ctr

Salt Lake City, Utah, United States

Site Status

Infectious Disease Physicians Inc

Annandale, Virginia, United States

Site Status

Univ of Virginia Health Sciences Ctr

Charlottesville, Virginia, United States

Site Status

Univ of Wisconsin

Madison, Wisconsin, United States

Site Status

Royal Brisbane Hosp

Herston, , Australia

Site Status

Pulmologisches Zentrum Der Stadt Wien

Vienna, , Austria

Site Status

Hosp Evandro Chagas Fioernz

Manguinhos RJ, , Brazil

Site Status

Castelo

São Paulo, , Brazil

Site Status

Fundacao Zerbini Casa Da Aids

São Paulo, , Brazil

Site Status

Hosp Do Servidor Publico Estadual De Sao Paulo

São Paulo, , Brazil

Site Status

Hosp Heliopolis

São Paulo, , Brazil

Site Status

Saint Paul's Hosp

Vancouver, British Columbia, Canada

Site Status

Ottawa General Hospital

Ottawa, Ontario, Canada

Site Status

Sunnybrook Health Science Ctr

Toronto, Ontario, Canada

Site Status

Toronto Gen Hosp

Toronto, Ontario, Canada

Site Status

Clinique Medicale du Quartier Latin

Montreal, Quebec, Canada

Site Status

Clinique Medicale L'Actuele

Montreal, Quebec, Canada

Site Status

Montreal Chest Institute

Montreal, Quebec, Canada

Site Status

Righospitalet

Copenhagen, , Denmark

Site Status

Hvidovre Univ Hosp

Hvidovre, , Denmark

Site Status

Odense Univ Hosp

Odense C, , Denmark

Site Status

CHU De Bicetre

Paris, , France

Site Status

Groupe Hospitalier Bichat-Claude Bernard

Paris, , France

Site Status

Hopital Gustave Dron

Tourcoing, , France

Site Status

Hopital Paul Brousse

Villejuif, , France

Site Status

EPIMED

Berlin, , Germany

Site Status

Univ Zu Koeln

Cologne, , Germany

Site Status

Heinrich Heine Universitat

Düsseldorf, , Germany

Site Status

Klinikum Der Johann Wolfgang Goethe Universitat

Frankfurt, , Germany

Site Status

Allgemeines Krankenhaus St Georg

Hamburg, , Germany

Site Status

Aids Study Group Mannheim

Mannheim, , Germany

Site Status

Ctr of AIDS Diagnosis and Treatment

Warsaw, , Poland

Site Status

Ponce Univ Hosp

Ponce, , Puerto Rico

Site Status

Miller

Belford Gardens, , South Africa

Site Status

Cyrildene

Johannesburg, , South Africa

Site Status

Hosp Germans Trias I Pujol

Barcelona, , Spain

Site Status

Hosp Carlos III

Madrid, , Spain

Site Status

Hosp De Mostoles

Madrid, , Spain

Site Status

Hosp Doce De Octubre

Madrid, , Spain

Site Status

Hosp La Paz

Madrid, , Spain

Site Status

Hosp Virgen Del Rocio

Seville, , Spain

Site Status

Universitatsspital Zurich

Zurich, , Switzerland

Site Status

Brighton Gen Hosp

Brighton, , United Kingdom

Site Status

Chelsea and Westminster Hosp

London, , United Kingdom

Site Status

Imperial College School of Medicine

London, , United Kingdom

Site Status

Royal Free Hosp

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Brazil Canada Denmark France Germany Poland Puerto Rico South Africa Spain Switzerland United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

M98-888

Identifier Type: -

Identifier Source: secondary_id

285D

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.